Table 3.
Factors Associated With Virologic Suppression in Adults With Pretreatment Drug Resistance Detected at the 20% Threshold
| Characteristic | Unadjusted HR (95% CI) | P Value | Adjusted HR (95% CI) | P Value |
|---|---|---|---|---|
| Pretreatment drug resistance | … | .06 | … | .09 |
| No PDR | 1 | … | 1 | … |
| Only NNRTI PDR | 0.84 (0.64–1.11) | … | 0.90 (0.68–1.18) | … |
| Both NNRTI/NRTI PDR | 0.42 (0.16–1.12) | … | 0.41 (0.15–1.10) | … |
| Age at initiation/5 years | 1.02 (1.00–1.05) | .11 | 1.03 (1.00–1.06) | .06 |
| Sex | … | .01 | … | .69 |
| Female | 1 | … | 1 | … |
| Male | 0.82 (0.70–0.96) | … | 0.97 (0.82–1.14) | … |
| CD4 at initiation (100 cells/mm3) | 1.06 (1.03–1.09) | <.001 | 1.03 (1.00–1.06) | .10 |
| Viral load (copies/mL) | … | <.001 | … | <.001 |
| ≤10000 | 1 | … | 1 | … |
| 10000–100000 | 0.74 (0.61–0.88) | … | 0.75 (0.62–0.90) | … |
| >100000 | 0.47 (0.38–0.56) | … | 0.48 (0.39–0.59) | … |
| Visual analogue scale adherence (%) | … | .001 | … | .003 |
| <95 | 1 | … | 1 | … |
| ≥95 | 1.40 (1.14–1.73) | … | 1.37 (1.11–1.70) | … |
Abbreviations: CI, confidence interval; HR, hazard ratio; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PDR, pretreatment drug resistance.